Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen

AIDS

Volumn 16, Issue 1, 2002, Pages 47-52

  Casado, Jose L ^a   Moreno, Santiago ^a   Hertogs, Kurt ^a   Dronda, Fernando ^a   Antela, Antonio ^a   Dehertogh, Pascale ^a   Perez Elías, María J ^a   Moreno, Ana ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Dual protease inhibitor therapy; Genotypic mutations; Key mutations; Nelfinavir; Pharmacokinetics; Resistance; Salvage therapy; Saquinavir

Indexed keywords

NELFINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT FAILURE; VIREMIA; VIRUS LOAD; VIRUS RESISTANCE; VIRUS TYPING;

ADULT; AGED; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; NELFINAVIR; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; SALVAGE THERAPY; SAQUINAVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0037016433     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200201040-00007     Document Type: Article

References (27)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV infected patients
3. Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents
4. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients
5. Saquinavir pharmacokinetic alone and in combination with nelfinavir in HIV-infected patients
6. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: A randomized trial
7. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir
8. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy
9. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1 infected individuals
10. Novel four-drug salvage treatment regimens after failure of a HIV type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virological outcome
11. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure
12. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens
13. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
14. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
15. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies
16. Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft-gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance
17. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotyic-guided therapy: Pharmacological data from the Viradapt study
18. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
19. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus
20. Penetration of HIV-1 protease inhibitors into CSF and semen
21. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy
22. Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy
23. Genetic correlates of virological response to an indinavir-containing salvage regimen in patients with nelfinavir failure
24. Predicting cross-resistance to nelfinavir in the absence of the D30N mutation
25. Impact of drug resistance mutations on virologic response to salvage therapy
26. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients with whom previous protease inhibitor therapy had failed
27. Practical implications for the interpretation of minimum plasma concentrations/inhibitory concentration rations